FibroBiologics, Inc. (FBLG) has recently disclosed the potential for its fibroblast therapy platform to be extended to additional therapeutic indications. In February 2026, the U.S. Patent and Trademark Office issued U.S. Patent No. 12,544,407 that covers treating bone diseases or disorders, including osteoporosis, with the use of fibroblast cells. In addition, the company recently announced the expansion of its wound care platform into the treatment of patients with acute and chronic burn injuries, with preclinical burn models showing treatment with CYWC628 being associated with favorable modulation of cytokine levels to support tissue repair and reduce inflammation. The company recently completed site onboarding ahead of its planned Phase 1/2 clinical trial of CYWC628 in patients with diabetic foot ulcers, which we anticipate initiating in the near future.
